Non-Small Cell Lung Cancer (NSCLC)
PD-L1 IHC 28-8 pharmDx
IVD
PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (nsNSCLC), non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, gastric cancer, and esophageal cancer, tissues using EnVision FLEX visualization system on Autostainer Link 48.
It is desirable to measure PD-L1 expression by 28-8 kit in determining whether or not the following drugs can be administered.
・Nivolumab [recombinant] for the patients with non-squamous NSCLC or head-and-neck cancer patients who have been treated with chemotherapy previously.
・Combination therapy of nivolumab [recombinant] and chemotherapy for NSCLC patients or gastric cancer patients who have not been treated with chemotherapy.
・Combination therapy of nivolumab [recombinant] and ipilimumab for melanoma patients.
If it is not possible to measure PD-L1 expression using 28-8 kit, refer to the packaging insert of the drugs, and appropriately judge the adequacy of administration.
Interpretation training is now available for PD-L1 IHC 28-8 pharmDx. To learn more, visit PD-L1 IHC 28-8 pharmDx eLearning.
PD-L1 IHC 28-8 pharmDx is subject to an exclusive trademark license to Agilent Technologies, Inc. OPDIVO® is a trademark owned by ONO in Japan, Korea and Taiwan and by Bristol-Myers Squibb in the rest of the world. YERVOY® is a trademark owned by Bristol-Myers Squibb.
Reg. Status: IVD
Product Details
Featured References
- Product Description References
-
1. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373:1627-39.
2. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Eng J Med 2012; 366:2455-2465.
3. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856-67.
4. Hellmann MD, Paz-Ares L, Caro RB, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med 2019;381:2020-31.
5. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–84.
6. Postow M, Chesney J, Pavlick A, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015;372:2006-17.
7. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
8. Janjigian YY, Shitara K, Moehler M, et. al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021;398: 27-40.
9. Doki, Y.; Ajani, J.A.; Kato, K.; et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022, 386(5), 449-462.
